xCellSense® quantifies drug sensitivity and combination synergy in primary NHL samples and profiles responders across lymphoma subtypes.
Request a Quote
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of diseases treated largely with multi-agent regimens. The key questions are which combinations work, in which subtypes, and which patients respond.
1
Combination design
sponsor asset alone and with CHOP-backbone and other agents, with pairwise synergy quantification
2
Responder profiling
Sensitivity scoringthat separates responders from non-responders
3
Subtype-resolved analysis
Response profiled across lymphoma subtypes
4
Optional genomics
Link mutational profile to functional response
Defensible rationale for combination and responder enrichment across heterogeneous lymphoma subtypes.
Key Deliverables
A scientist — not a sales desk — will scope a tailored AML study and return a design and timeline.
